Friday, Idera Pharmaceuticals Inc. (IDRA) a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors or TLR, announced the appointment of Rahul Jasuja, as Vice President of Corporate Development. Jasuja previously served as Managing Director, Life Sciences at MDB Capital Group, a life sciences and technology Merchant and Investment Bank located in Santa Monica, CA.
"Rahul brings extensive and relevant scientific understanding and experience in the capital markets to Idera. We welcome Rahul to our team and expect him to play a key role in the Company as we continue to advance our drug discovery and development programs with agonists, antagonists, and antisense targeted to TLRs," said Sudhir Agrawal,Chief Executive Officer and Chief Scientific Officer.
For comments and feedback: editorial@rttnews.com